Current Statistical Challenges in Oncology Clinical Trials in the Era of Targeted Therapy

References

• Barker, A.D., Sigman, C.C., Kelloff, G.J., Hylton, N.M., Berry, D.A., and Esserman, L.J. (2009), “I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy,” Clinical Pharmacology and Therapeutics, 86, 97–100.
   Google Scholar
• Begg, C.B. (2015Ethical Concerns About Adaptive Randomization,” Clinical Trials, 12, 101.
   Google Scholar
• Berry, S.M., Broglio, K.R., Groshen, S., and Berry, D.A. (2013Bayesian Hierarchical Modeling of Patient Subpopulations: Efficient Designs of Phase II Oncology Clinical Trials,” Clinical Trials, 10, 720–734.
   Google Scholar
• Broglio, Kr., and Berry, D.A. (2009Detecting an Overall Survival Benefit That is Derived From Progression-Free Survival,” JNCI Journal of the National Cancer Institute, 101:1642–1649.
   Google Scholar
• Brookings events Discussion Guide (2014), Expert Workshop: Pioneering Statistical Approaches to Accelerate Drug Development through Adaptive Trial Designs, available at . http://www.brookings.edu/∼/media/events/2014/3/27-adaptive-trial-design-clinical-trials/discussion-guide.pdf
   Google Scholar
• Buyse, M. (2000Randomized Designs for Early Trials of New Cancer Treatments—An Overview,” Drug Information Journal, 34, 387–396.
   Google Scholar
• Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., Swain, S. M., Prowell, T., Loibl, S., Wickerham, D. L., Bogaerts, J., Baselga, J., Perou, C., Blumenthal, G., Blohmer, J., Mamounas, E. P., Bergh, J., Semiglazov, V., Justice, R., Eidtmann, H., Paik, S., Piccart, M., Sridhara, R., Fasching, P. A., Slaets, L., Tang, S., Gerber, B., Geyer, C. E. Jr., Pazdur, R., Ditsch, N., Rastogi, P., Eiermann, W., and von Minckwitz, G. (2014Pathological Complete Response and Long-Term Clinical Benefit in Breast Cancer: The CTNeoBC Pooled Analysis,” Lancet, 384, 164–172.
   Google Scholar
• D’Agostino, R.B. Jr. (1998Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Nonrandomized Control Group,” Statistics in Medicine, 17, 2265–2281.
   Google Scholar
• Dahlberg, S.E., Shapiro, G.I., Clark, J.W., and Johnson, B.E. (2014Evaluation of Statistical Designs in Phase I Expansion Cohorts: The Dana-Farber/Harvard Cancer Center Experience,” JNCI, 106, 1–6.
   Google Scholar
• FDA (2012Guidance for Industry: Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products, available at http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm332181.pdf
   Google Scholar
• ——— (2014Guidance for Industry Expedited Programs for Serious Conditions—Drugs and Biologics, available at http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf
   Google Scholar
• Food and Drug Safety Innovation Act (2012), available at http://www.gpo.gov/fdsys/pkg/BILLS-112s3187enr/pdf/BILLS-112s3187enr.pdf
   Google Scholar
• Gray, R.J. (1988A Class of K-Sample Tests for Comparing the Cumulative Incidence of Competing Risks,” Annals of Statistics, 16, 1141–1154.
   Google Scholar
• Guidance for Industry Pathological (2014Guidance for Industry Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval, available at http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm305501.pdf
   Google Scholar
• Heinrich, M.C., Joensuu, H., Demetri, G.D., Corless, C. L., Apperley, J., Fletcher, J. A., Soulieres, D., Dirnhofer, S., Harlow, A., Town, A., McKinley, A., Supple, S. G., Seymour, J., DiScala, L., van Oosterom, A., Herrmann, R., Nikolova, Z., McArthur, A. G., and Imatinib Target Exploration Consortium Study B2225 (2008Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to be Associated With Imatinib-Sensitive Tyrosine Kinases,” Clinical Cancer Research, 14, 2717–2725.
   Google Scholar
• Herbst, R.S., Gandara, D.R., Hirsch, F.R., Redman, M. W., LeBlanc, M., Mack, P. C., Schwartz, L. H., Vokes, E., Ramalingam, S. S., Bradley, J. D., Sparks, D., Zhou, Y., Miwa, C., Miller, V. A., Yelensky, R., Li, Y., Allen, J. D., Sigal, E. V., Wholley, D., Sigman, C. C., Blumenthal, G. M., Malik, S., Kelloff, G. J., Abrams, J. S., Blanke, C. D., and Papadimitrakopoulou, V. A. (2015Lung Master Protocol (Lung MAP) – A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400,’’ Clinical Cancer Research, 21, 1514–1524.
   Google Scholar
• Herbst, R.S., Gandara, D., and Papadimitrakopoulou, V. (2015How the Lung-MAP Clinical Trial is Responding to Changing Science,” The Cancer Letter, 41, 12–15.
   Google Scholar
• Hey, S.P., and Kimmelman, J. (2015Are Outcome-Adaptive Allocation Trials Ethical?" Clinical Trials, 12, 102–106.
   Google Scholar
• Hintze, J. (2013), Power Analysis & Sample Size Software® PASS 12, Kaysville, UT: NCSS, LLC. Available at www.ncss.com.
   Google Scholar
• Hodi, F.S., O’Day, S.J., McDermott, D.F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbé, C., Peschel, C., Quirt, I., Clark, J. I., Wolchok, J. D., Weber, J. S., Tian, J., Yellin, M. J., Nichol, G. M., Hoos, A., and Urba, W. J. (2010Improved Survival With Ipilimumab in Patients With Metastatic Melanoma,” New England Journal of Medicine, 363, 711–723.
   Google Scholar
• Kelley, M.K., and Abdus, S.W. (2013Weighted Log-Rank Statistic to Compare Shared-Path Adaptive Treatment Strategies,” Biostatistics, 14, 299–312.
   Google Scholar
• Kim, E.S., Herbst, R.S., Wistuba, II, Lee, J.J., Blumenschein, G.R. , Jr., Tsao, A., Stewart, D. J., Hicks, M. E., Erasmus, Jr. J., Gupta, S., Alden, C. M., Liu, S., Tang, X., Khuri, F. R., Tran, H. T., Johnson, B. E., Heymach, J. V., Mao, L., Fossella, F., Kies, M. S., Papadimitrakopoulou, V., Davis, S. E., Lippman, S. M., and Hong, W. K. (2011The BATTLE Trial: Personalizing Therapy for Lung Cancer,” Cancer Discovery, 1, 44–53.
   Google Scholar
• Latimer, N.R., Abrams, K.R., Lambert, P.C., Crowther, M., Wailoo, A., Morden, J., Akehurst, R., and Campbell, M. (2014Adjusting for Treatment Switching in Randomized Controlled Trials—A Simulation Study and a Simplified Two-Stage Method,” Statistical Methods in Medical Research, 0, 1–28.
   Google Scholar
• LaVange, L., and Sridhara, R. (2014Statistical Considerations in Designing Master Protocols,'' in Presented at Innovations in Breast Cancer Drug Development—Next Generation Oncology Trials, Breast Cancer Workshop. Available at http://www.fda.gov/downloads/Drugs/NewsEvents/UCM423368.pdf
   Google Scholar
• Li, Z., Valenstein, M., Pfeiffer, P., and Ganoczy, D. (2014A Global Logrank Test for Adaptive Treatment Strategies Based on Observational Studies,” Statistics in Medicine, 28, 760–771.
   Google Scholar
• Lokhnygina, Y., and Helterbrand, J.D. (2007Cox Regression Methods for Two-Stage Randomization Designs,” Biometrics, 63, 422–428.
   Google Scholar
• Lopez-Chavez, A., Tomas, A., Raffeld, M., Morrow, B., Kelly, R., Carter, C. A., Guha, U., Killian, K., Lau, C. C., Abdullaev, Z., Xi, L., Pack, S., Meltzer, P. S., Corless, C. L., Sandler, A., Beadling, C., Warrick, A., Liewehr, D. J., Steinberg, S. M., Berman, A., Doyle, A., Szabo, E., Wang, Y., and Giaccone, G. (2015Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial,” Journal of Clinical Oncology, 33, 1000–1007.
   Google Scholar
• Lunceford, J.K., and Davidian, M. (2004Stratification and Weighting via the Propensity Score in Estimation of Causal Treatment Effects: A Comparative Study,” Statistics in Medicine, 23, 2937–2960.
   Google Scholar
• Mok, T.S., YuL. W., Y.L. W., Thogprasert, S., Yang, C. H., Chu, D. T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J. J., Chewaskulyong, B., Jiang, H., Duffield, E. L., Watkins, C. L., Armour, A. A., and Fukuoka, M. (2009Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma,” New England Journal of Medicine, 361, 947–957.
   Google Scholar
• National Cancer Institute, A Joint NCTN/NCI Clinical Trial (2015), Molecular Analysis of Therapy Choice, available at . http://dctd.cancer.gov/MajorInitiatives/NCI-MATCH.pdf
   Google Scholar
• Rituxan US Package Insert (2014), Prescribing Information RITUXAN®. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103705s5432lbl.pdf
   Google Scholar
• Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J. F., Testori, A., Grob, J. J., Davidson, N., Richards, J., Maio, M., Hauschild, A., Miller, W. H. Jr., Gascon, P., Lotem, M., Harmankaya, K., Ibrahim, R., Francis, S., Chen, T. T., Humphrey, R., Hoos, A., and Wolchok, J. D. (2011Ipilimumab Plus Dacarbazine for Previously Untreated Metastatic Melanoma,” New England Journal of Medicine, 364, 2517–2526.
   Google Scholar
• Robins, J.M., Hernan, M.A., and Brumback, B. (2000Marginal Structural Models and Causal Inference in Epidemiology,” Epidemiology, 11, 550–560.
   Google Scholar
• Uno, H., Claggett, B., Tian, L., Inoue, E., Gallo, P., Miyata, T., Schrag, D., Takeuchi, M., Uyama, Y., Zhao, L., Skali, H., Solomon, S., Jacobus, S., Hughes, M., Packer, M., and Wei, L. J. (2014Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis,” Journal of Clinical Oncology, 32, 2380–2385.
   Google Scholar
• Wong, A., Leaf-Herrmann, W., and Leahy, L.W. (2014Novel Clinical Trial Designs in Oncology: An Histology-Independent Approach, IN VIVO: The Business & Medicine Report May 2014,’’. available at http://www.imsconsultinggroup.com/deployedfiles/consulting/Global/Content/How%20We%20Help/Strategy%20&%20Portfolio/novel_clinical_trial_designs_in_oncology.pdf
   Google Scholar
• Xie, J., and Liu, C. (2005Adjusted Kaplan-Meier Estimator and Log-Rank Test With Inverse Probability of Treatment Weighting for Survival Data,” Statistics in Medicine, 24, 3089–3110.
   Google Scholar
• Zhang, Z. (2007Estimating the Current Treatment Effect With Historical Control Data,” JP Journal of Biostatistics, 1, 217–247.
   Google Scholar
• Zhang, D., and Quan, H. (2009Power and Sample Size Calculation for Log-Rank Test With a Time Lag in Treatment Effect,” Statistics in Medicine, 28, 864–879.
   Google Scholar
• Zhang, L., Ko, C., Tang, S., and Sridhara, R. (2013Relationship Between Progression-Free Survival and Overall Survival Benefit: A Simulation Study,” Therapeutic Innovation & Regulatory Science, 47, 95–100.
   Google Scholar